Cystic fibrosis (CF) investigators at Seattle Children’s work closely with their colleagues at the University of Washington (UW), across the country and around the world. Funding from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) and the National Institutes of Health (NIH) helps support both our infrastructure and specific research projects. Here are a few of the groups and programs we are associated with.
CF Therapeutics Development Network
As one of the eight founding members of the CF Therapeutics Development Network (TDN), clinical investigators and research team members from Children’s and the UW formed the Seattle Therapeutics Development Center in 1998. Funded through CFFT, this network now includes more than 75 centers across the country. Its mission is to ensure quality and safety in CF clinical trials and to expedite the development of new and better treatments for CF and to ensure quality and safety in CF clinical trials.
CF Research Development Program
Funded through CFFT, the Cystic Fibrosis Research Development Program (RDP) is a partnership between scientists and clinical investigators at the UW and Children’s. The RDP team specializes in laboratory and translational research related to CF lung infections, advancing our knowledge of areas such as Pseudomonas aeruginosa biology (a common bacterium that causes death in humans and animals) and response to infection and inflammation. The program supports core facilities, access to specimen samples, pilot research projects and career development for the next generation of CF researchers.
CF Research and Translation Center (P30 Program)
Children’s and UW researchers also work together through the Cystic Fibrosis Research and Translation Center. Funded by the NIH, the center is designed to serve as a national resource to enhance the translation of promising laboratory findings into novel therapies. The center has a special focus on infection and inflammation as well as the development of promising new therapeutic approaches related to digestion, malnutrition, liver disease and chronic lung disease.